Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)

NCT06999902 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

230

Enrollment

INDUSTRY

Sponsor class

Conditions

Focal Seizure

Interventions

DRUG: 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks
DRUG: Placebo

Sponsor

Praxis Precision Medicines